Company Filing History:
Years Active: 2022
Title: The Innovations of Stephen Mark Anderton
Introduction
Stephen Mark Anderton is a notable inventor based in Edinburgh, Lothian, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on the stimulation of IL-12 production, which plays a crucial role in the immune response against cancer.
Latest Patents
Stephen Mark Anderton holds a patent for a method titled "Treatment of cancer by stimulation of IL-12 production." This invention relates to a compound and composition designed to stimulate IL-12 and IFN-γ production. The specific compounds involved include tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alaninate, or a pharmaceutically acceptable salt, hydrate, or solvate thereof; and N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alanine. This patent highlights his commitment to advancing cancer therapies.
Career Highlights
Stephen is associated with Macrophage Pharma Limited, where he continues to work on innovative solutions for cancer treatment. His research has the potential to impact the lives of many patients suffering from cancer. With a focus on immunotherapy, he aims to enhance the body's natural defenses against tumors.
Collaborations
Stephen has collaborated with notable colleagues, including David Festus Charles Moffat and Martin John Perry. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of cancer research.
Conclusion
Stephen Mark Anderton's contributions to cancer treatment through his innovative patent demonstrate his dedication to improving patient outcomes. His work at Macrophage Pharma Limited and collaborations with esteemed colleagues further emphasize his role as a significant figure in the field of medical research.